GW Pharmaceuticals — Merger or Acquisition (February 2021)
12 slides from GW Pharmaceuticals's merger presentation, Feb 26, 2021
Slide 1: Corporate Overview: Innovating to Transform the Lives of Patients
CORPORATE OVERVIEW INNOVATING TO TRANSFORM THE LIVES OF PATIENTS FEBRUARY 23, 2021 Sara © 2021 Jazz Pharmaceuticals. All rights reserved. JZP-258 Trial Participant
Slide 2: Forward-Looking Statements
Life-Changing Medicines. Redefining Possibilities. Forward-Looking Statements “Safe Harbor” Statement Under The Private Securities Litigation Reform Act of 1995 This communication contain forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals’ future fi
Slide 3: Forward-Looking Statements (Continued)
Life-Changing Medicines. Redefining Possibilities. Forward-Looking Statements “Safe Harbor” Statement Under The Private Securities Litigation Reform Act of 1995 (Continued from Previous Slide) obtaining and maintaining adequate coverage and reimbursement for the company’s products; identifying and a
Slide 4: Non-GAAP Financial Measures
Life-Changing Medicines. Redefining Possibilities. Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-
Slide 5: Additional Information and Where to Find It
Additional Information and Where to Find It In documents connection with with the the SEC proposed regarding transaction, the proposed GW Pharmaceuticals transaction. The intends definitive to proxy file a proxy statement statement (if and with when the available) SEC. Each will of be Jazz mailed Ph
Slide 6: Transaction Overview: GW Pharmaceuticals plc
TRANSACTION OVERVIEW: GW PHARMACEUTICALS PLC
Slide 7: GW Acquisition Expected to Drive Substantial Shareholder Value
GW Acquisition Expected to Drive Substantial Shareholder Value Creates an innovative, global, high-growth biopharma leader with a robust pipeline and one patient-centric mission Epidiolex has near-term blockbuster potential Combined Neuroscience business has global commercial and operational footpri
Slide 8: Global leaders in complementary areas
Global leaders #1 Sleep Disorders Unparalleled Leader in in complementary areas Franchise Cannabinoid Science SLEEP Addition of third DISORDERS -growth commercial franchise EPILEPSIES with blockbuster potential ONCOLOGY • Global commercial and Augments Jazz’s growing operational footprint to Europea
Slide 9: Increased Scale, Immediate, Enhanced Diversification
INCREASED SCALE IMMEDIATE, ENHANCED DIVERSIFICATION Total revenue ($B) Revenue contribution 100% 75% 50% JZP-4583 JZP-2583 25% 1 2 0% 2020 2022E 2022E-PF Products Acquired or Launched Since 2019 Accelerated, Double-Digit Top Line Revenue Growth Contribute >65% of Revenue in 2022 1 2020 pro forma = J
Slide 10: Transaction Expected to Deliver Substantial and Sustainable Value
Transaction Expected to Deliver Substantial and Sustainable Value Disciplined Allocation of Capital in Alignment With Our Strategic Priorities TRANSACTION ALIGNED TO LEVERAGING FINANCIAL DISCIPLINED USE OF CAPITAL CAPITAL ALLOCATION STRATEGY STRENGTH Accelerates revenue Expect to be EPS accretive $2
Slide 11: Robust, Innovative Pro Forma Research and Development Pipeline
Robust, Innovative Pro Forma Research and Development Pipeline PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY Undisclosed targets JZP-324 JZP-3854 Vyxeos JZP-258 Neuroscience Oxybate extended-release formulation Essential tremor (Phase 2b) • AML or HR-MDS >60 yrs (AML18) 5 Idiopathic hypersomnia •
Slide 12: Transaction Overview
Transaction Overview • Holders of GW ADSs, which each represent 12 GW ordinary shares, will be entitled to receive $220 for each GW ADS Purchase Price — Representing $200 in cash and $20 in shares of Jazz stock, subject to a 10% collar centered on Jazz’s closing share price on February 1, 2021 • Tot
GW Pharmaceuticals — Merger or Acquisition (February 2021) on 6ix